On Nov 11st, 2019, Bridge Point Capital (BPC) signed a strategic partnership agreement with LBYH Medical Technology (LBYH) to pave the way for extensive cooperation in the near future.
LBYH is co-founded by industry experts with extensive experience in healthcare investment, medical device regulation, quality management, and clinical research. LBYH is dedicated to providing specialized technology services for early-stage medical device companies to help lower their cost of product research and speed up their market entry process. LBYH provides strategic and practical technology consulting services and offers highly integrated solutions including research assistance, registration, regulations, clinical trials and testing, contract development and manufacturing organization (CDMO) and capital financing. The mission of LBYH is to create a smooth process for medical device innovators to focus on running their business, and to accelerate their R&D and commercialization.
Both parties agreed that forming a strategic partnership will benefit both companies in sharing complementary advantages and resources, improving the quality of service, and creating further business opportunities. Based on the agreement, BPC and LBYH will initially establish collaboration in the following areas:
1. Co-host a worldwide medical device innovation competition in 2020 where international medical device companies can compete for sponsorship and related support from local Chinese industrial parks.
2. Provide international medical companies with professional services such as local government relationship management, regulation compliance, and obtaining preferential economic policies by utilizing both parties’ experience and influence in the U.S.-China cross-border healthcare market.
“The strategic collaboration between BPC and LBYH is not only a win-win situation for the two companies, but also further improves the foreign project launching process in industrial parks in China and elevates the worldwide influence of the industrial parks,” Mark Young, BPC Co-Founder and Chief Investment Officer, comments on this partnership, “We will leverage our extensive experience and network in the healthcare and financial industry in the U.S., combining it with the LBYH’s local resources and experience in obtaining NMPA approval, we can provide a high-quality process for foreign companies to smoothly and successfully enter the China market.
Bridge Point Capital is a private equity firm based in New York with a focus on U.S.-China cross-border investment. We invest in disruptive late-stage healthcare companies that can benefit from penetrating the vast, yet unexplored, Chinese healthcare market. We aim to leverage our expertise in both healthcare and capital markets to provide the best investment platform we possibly can for our investors.